Apyx Narrows 2026 Expense Target, Holds Revenue
Suppliers to medical aesthetics device makers should expect tighter cost control as Apyx targets $41 million to $42.5 million in operating expenses.
Updated on Nov. 7, 2026 in Healthcare

Apyx Medical Corporation held its 2026 revenue forecast at $59 million to $60 million while lowering its 2026 operating expense target to $41 million to $42.5 million, down from less than $45 million. For operators in medical device and aesthetics supply, the narrower cost range signals tighter expense planning for the company's Surgical Aesthetics line.
Why it matters
The company kept its top-line outlook unchanged while narrowing its cost guidance, a shift that points to tighter spending control rather than a change in demand. Third-quarter results showed Surgical Aesthetics revenue up 17% to $13 million, while original-equipment-manufacturer revenue fell 42%, leaving the mix tilted toward the company's own aesthetics products.
Third-quarter revenue reached $14 million, up 9% from the prior year, with Surgical Aesthetics growing 17% to $13 million. Quarterly operating expenses rose to $9.6 million from $9.1 million, and the net loss narrowed to $1.8 million from $2 million.
The players
Apyx Medical Corporation
A Nasdaq-listed medical device company whose Surgical Aesthetics line drives most of its revenue.
The details
Apyx's 2026 revenue outlook includes $54 million to $55 million from Surgical Aesthetics and about $5 million from original-equipment-manufacturer sales. Gross margins are projected at 63% to 65%. By replacing its prior expense ceiling of less than $45 million with a $41 million to $42.5 million range, the company is signaling a tighter cost structure while keeping revenue targets fixed, which means margin improvement would have to come from spending discipline.
Timeline
Full-year 2025 revenue totaled $52.8 million.
Third-quarter results for the three months ended Sept. 30 reported revenue of $14 million.
The 2026 revenue forecast of $59 million to $60 million and revised operating expense target were issued with the third-quarter results.
Market Landscape
Apyx's revision follows its earlier guidance, which set a broader operating expense ceiling below $45 million. The company's revenue mix, with Surgical Aesthetics supplying $54 million to $55 million of the 2026 forecast, shows the business depends on its own aesthetics line more than on OEM sales.
Operators in medical device supply and aesthetics should watch whether the company's cost reductions hold through 2026. Vendors and distributors tied to Surgical Aesthetics may face closer pricing scrutiny as the company seeks gross margins of 63% to 65%.
The takeaway
The key operating signal is that Apyx is holding revenue guidance while tightening costs, so margin gains depend on expense discipline. Operators tracking medical device supply should watch the company's next quarterly filing for whether operating expenses stay within the $41 million to $42.5 million range.
Further reading
For broader context on how medical device makers manage costs and guidance, see the Healthcare section.
Source note: This article includes information reported by TokenPost.




